학술논문
A new prognostic model including immune biomarkers, genomic proliferation tumor markers (AURKA and MYBL2) and clinical-pathological features optimizes prognosis in neoadjuvant breast cancer patients
Document Type
Article
Author
Source
In: Frontiers in Oncology . (Frontiers in Oncology, 2023, 13)
Subject
Language
English
ISSN
2234943X